Delivery Order SPE2DB24D9113-SPE2DB25FEQDM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc. on September 3, 2025, for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order for delivery to Park Ridge, IL. The contract utilizes a firm fixed-price structure with an ultimate completion date of September 4, 2025, and no set-aside designation...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $12,792.31 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge location with completion expected by July 24, 2025. This delivery order was awarded without a set-aside designation, allowing the vendor to compete in the open...
- The Defense Logistics Agency awarded a delivery order valued at $25,868.10 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a product delivery under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The contract carries no set-aside designation, allowing the woman-owned small business to compete on an...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- The U.S. Defense Department's Medical Supply Chain division awarded a delivery order valued at $34,490.80 to DMS Pharmaceutical Group Inc. on August 28, 2025, for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order with a firm fixed-price arrangement and an ultimate completion date of August 29, 2025. The contract carries no set-aside designation,...
- The Defense Logistics Agency awarded a $4,311.35 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on August 29, 2025, for the supply of Xtandi 40 mg capsules (120-count units). This award carries an ultimate completion date of September 2, 2025, and represents a standard delivery order issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA. The contract contains no set-aside designation, allowing the woman-owned small business to compete directly...
- The Defense Logistics Agency awarded a $43,113.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120-count units), with an ultimate completion date of August 11, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this contract at its Park Ridge location. This delivery order was issued without a set-aside designation, allowing the vendor to compete...
- The Defense Logistics Agency awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (quantity: 120). This firm fixed-price delivery order, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a continuation of the ongoing pharmaceutical supply relationship between the agency and the vendor. The award carries no...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. on September 9, 2025, for the supply of Xtandi 40 mg tablets (120-count units). DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this order at its Park Ridge location with an ultimate completion date of September 10, 2025. This delivery order was issued without a set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $17,245.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, executed on September 2, 2025, with an ultimate completion date of September 3, 2025, carries no set-aside designation. The award leverages DMS Pharmaceutical Group's existing Indefinite Delivery...
- SPE2DB24D9113Indefinite Delivery Contract
- SPE2DB24D9113-SPE2DB25FEQDMDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $17,245.40 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg capsules (120-count units). This award, issued on September 11, 2025, with an ultimate completion date of September 12, 2025, represents a single delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The contract carries no set-aside designation, and the product will be delivered to Park Ridge, Illinois, where the vendor is based. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler operating since 2001, serves as a critical supplier within the federal pharmaceutical supply chain. The delivery order falls under the vendor's comprehensive $500 million SPE2DB indefinite delivery contract with DLA, which extends through November 2026 and enables the issuance of firm fixed-price delivery orders for an extensive range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide. Xtandi, an oncology treatment medication, aligns with the vendor's established portfolio of specialty pharmaceutical products delivered to military health systems and federal healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.2k | 9/11/25 |